Perspective
Dec. 16, 2010
The Matrixx Revisited
A pending Supreme Court case could either lead to greater clarity or more confusion for companies and counsel. By Jared L. Kopel of Wilson Sonsini Goodrich & Rosati.
The first part of this article provided the background to Matrixx Initiatives Inc. et al. v. Siracusano et al., No. 09-1156, which will be heard by the U.S. Supreme Court on Jan. 10, 2011. The case concerns whether plaintiffs may plead a securities fraud claim against a pharmaceutical company for nondisclosure of adverse event reports where there is no statistically significant evidence that the company's product caused the adverse ev...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In